• About Us
  • Privacy Policy
  • Contact
Mortgage Insurance Center
  • Home
  • Mortgages
  • Health Insurance
  • Home Insurance
  • Life insuranace
  • Finance Laws
    • Banking Laws
    • Assets
    • Interest Rate
    • Loans
No Result
View All Result
  • Home
  • Mortgages
  • Health Insurance
  • Home Insurance
  • Life insuranace
  • Finance Laws
    • Banking Laws
    • Assets
    • Interest Rate
    • Loans
No Result
View All Result
Mortgage Insurance Center
No Result
View All Result
Home Health Insurance

HIRA reviews reimbursing antidiabetic combo therapies

by Staff
June 15, 2022
in Health Insurance
0
HIRA reviews reimbursing antidiabetic combo therapies
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

[ad_1]


The Health Insurance Review and Assessment Service (HIRA) has been analyzing how new reimbursements for antidiabetic combination therapies mixing oral SGLT-2 and DPP-4 inhibitors would affect the national health insurance financing.


If the national health insurance covers SGLT-2 inhibitors in combination with DPP-4 inhibitors, which are used for a broad diabetic population, it will significantly increase government spending on health insurance.


Kim Ae-ryun, director-general of the Pharmaceuticals Benefits Department at the Health Insurance Review Assessment and Service (HIRA), speaks during a news conference on Tuesday.
Kim Ae-ryun, director-general of the Pharmaceuticals Benefits Department at the Health Insurance Review Assessment and Service (HIRA), speaks during a news conference on Tuesday.


Kim Ae-ryun, director-general of the Pharmaceuticals Benefits Department at HIRA, said that the health insurance agency reviewed the criteria for reimbursing the combination of SGLT-2 inhibitors and DPP-4 inhibitors among oral diabetes treatments.


“Now, we are analyzing the reimbursement’s fiscal impact,” she told reporters on Tuesday.


More specifically, the government is reviewing reimbursement for three-drug combo, metformin+SGLT-2 inhibitor+DPP-4 inhibitor, another three-drug combo metformin+SGLT-2 inhibitor+thiazolidinediones(TZD), and two-drug combo mixing some of the SGLT-2 inhibitors with sulfonylurea or insulin.


Only some SGLT-2 inhibitors are eligible for reimbursement review because the HIRA excluded drugs that the Ministry of Food and Drug Safety banned to use in combo with other medicines.


In response to criticism that the HIRA’s review was too slow, Kim said HIRA would complete the evaluation on the drug combos within the legally-set assessment period of 150 days.


HIRA is also speeding up the re-evaluation of the medicines’ eligibility for the national health insurance coverage.


After HIRA noticed the plan for re-evaluation in March, it requested pharmaceutical companies of reimbursable drugs to submit related data for re-assessment. All 141 drug companies have completed data submission, HIRA said.


This year, HIRA will re-evaluate six agents for health insurance benefits — streptokinase/streptodornase, almagate, sodium alginate, eperisone hydrochloride, tiropramide hydrochloride, and adenine combo. HIRA chose the six considering reimbursement cases overseas and local insurance claims.


“We are reviewing each ingredient’s clinical usefulness at the working level and through expert advisory meetings,” Kim said. “We will deliberate it at an evaluation subcommittee and the pharmaceutical benefit review committee within the third quarter.”

[ad_2]

Source link

Previous Post

Crypto exchanges slash jobs as market turmoil triggers trading downturn

Next Post

Three Nominees for Florida Supreme Court Appear to Lean the Insurer Way

Next Post

Three Nominees for Florida Supreme Court Appear to Lean the Insurer Way

Popular Posts

Ajanta Pharma : Newspaper Advertisements
Life insuranace

Taiming Assurance Broker : Announcement on behalf of the major subsidiary Link-Aim Life Insurance Broker Co.,LTD. to distribute dividends.

by Staff
July 28, 2022
0

Close Provided by: TAIMING ASSURANCE BROKER CO.,LTD. SEQ_NO 4 Date of...

Read more

Taiming Assurance Broker : Announcement on behalf of the major subsidiary Link-Aim Life Insurance Broker Co.,LTD. to distribute dividends.

20% interest rate on credit cards! Here’s how to avoid paying those high rates :: WRAL.com

Sens. Murphy, Blumenthal, Colleagues Reintroduce the Behavioral Health Coverage Transparency Act – InsuranceNewsNet

$1 billion in loans still available for agricultural funding in Ohio

How Long Do Car Accidents Stay on Your Record?

Rocket Mortgage Classic Wagers: Pick To Finish Top-10

Load More

Popular Posts

The perks and pitfalls of adjustable-rate mortgages in 2022

by Staff
June 13, 2022
0

Ajanta Pharma : Newspaper Advertisements

Taiming Assurance Broker : Announcement on behalf of the major subsidiary Link-Aim Life Insurance Broker Co.,LTD. to distribute dividends.

by Staff
July 28, 2022
0

Propy introduces blockchain title and escrow service

Propy introduces blockchain title and escrow service

by Staff
May 26, 2022
0

Ajanta Pharma : Newspaper Advertisements

Taiming Assurance Broker : Announcement on behalf of the major subsidiary Link-Aim Life Insurance Broker Co.,LTD. to distribute dividends.

July 28, 2022

20% interest rate on credit cards! Here’s how to avoid paying those high rates :: WRAL.com

July 28, 2022
Edelweiss General Insurance launches India’s first on-demand, mobile telematics-based comprehensive motor insurance – SWITCH

Sens. Murphy, Blumenthal, Colleagues Reintroduce the Behavioral Health Coverage Transparency Act – InsuranceNewsNet

July 28, 2022

Categories

  • Assets
  • Banking Laws
  • Finance Laws
  • Health Insurance
  • Home Insurance
  • Interest Rate
  • Life insuranace
  • Loans
  • Mortgages

Tags

home loans mortgage personal loan
  • Privacy Policy
  • contact us

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • About Us
  • contact us
  • Home
  • Home 2
  • Home 3
  • Privacy Policy

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.